SCHEMBL21291527

SCHEMBL21291527

CC(=O)OCC(C)C1=C(C)C(=O)C2=C(CC[C@H]3C(C)(C)CCC[C@]23C)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ CYP19A1 P11511 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PTPN1 P18031 2/20 0.33
▸ CDC25A P30304 1/20 0.33
▸ DUSP3 P51452 1/20 0.33
▸ USP2 O75604 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CETP P11597 5/20 0.31
▸ PTPN2 P17706 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ FDPS P14324 1/20 0.31
▸ MAPKAPK2 P49137 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Royleanone SCHEMBL21291506 0.74 CYP3A4 (0.44) TP53CYP3A4CYP19A1USP2HSP90AA1
SCHEMBL22861865 0.70 FDPS (0.34) TP53CYP3A4CYP19A1FDPSEP300
SCHEMBL21291526 0.70 FDPS (0.34) TP53CYP3A4CYP19A1FDPSEP300
SCHEMBL22862021 0.66 EP300 (0.32) EP300
SCHEMBL22862020 0.66 EP300 (0.32) EP300
SCHEMBL15732245 0.66 EP300 (0.46) TP53CYP3A4CYP19A1USP2HSP90AA1
SCHEMBL22861861 0.64 EP300 (0.31) EP300
SCHEMBL22861862 0.64 EP300 (0.31) EP300
SCHEMBL22861873 0.64 FDPS (0.30) FDPSEP300
Taiwaniaquinone G SCHEMBL31237701 0.63 TSHR (0.36) TP53CYP3A4CYP19A1TSHRFDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019158359-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2019-08-22 — — WO disclosed
Send feedback